This gene encodes the third discovered human homologue of the Drosophila melanogaster type I membrane protein notch. In Drosophila, notch interaction with its cell-bound ligands (delta, serrate) establishes an intercellular signalling pathway that plays a key role in neural development. Homologues of the notch-ligands have also been identified in human, but precise interactions between these ligands and the human notch homologues remains to be determined.
Mutations in NOTCH3 have been identified as the underlying cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).[6] Mutations in NOTCH3 have also been identified in families with Alzheimer's disease.[7] Adult Notch3 knock-out mice show incomplete neuronal maturation in the spinal cord dorsal horn, resulting in permanently increased nociceptive sensitivity.[8] Mutations in NOTCH3 are associated to lateral meningocele syndrome.[9]
Pharmaceutical target
Notch3 is being investigated as a target for anti-cancer drugs, as it is overexpressed in several types of cancers.[10] Early clinical trials of Pfizer's PF-06650808, an anti-Notch3 antibody linked to a cytotoxic drug, showed efficacy against solid tumors.[11]
Mammalian evolution
An extensive cross-species investigation of the NOTCH3 gene has revealed unexpected natural diversity in a protein that is otherwise highly conserved among mammals. The analysis uncovered multiple cysteine-altering variants in jaguar[12] a rare splice isoform in humans shared with a small number of other species, and a regulatory-region deletion in Brandt’s bat.[13]
↑"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, etal. (September 1994). "Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3". Genomics. 23 (2): 408–419. doi:10.1006/geno.1994.1517. PMID7835890.
↑Figueiró HV, Li G, Trindade FJ, Assis J, Pais F, Fernandes G, etal. (July 2017). "Genome-wide signatures of complex introgression and adaptive evolution in the big cats". Science Advances. 3 (7) e1700299. Bibcode:2017SciA....3E0299F. doi:10.1126/sciadv.1700299. PMID28776029.
Joutel A, Tournier-Lasserve E (2002). "[Molecular basis and physiopathogenic mechanisms of CADASIL: a model of small vessel diseases of the brain]". Journal de la Societe de Biologie. 196 (1): 109–115. doi:10.1051/jbio/2002196010109. PMID12134625. S2CID86151374.
Guidetti D, Casali B, Mazzei RL, Dotti MT (2006). "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy". Clinical and Experimental Hypertension. 28 (3–4): 271–277. doi:10.1080/10641960600549223. PMID16833034. S2CID360190.
Larsson C, Lardelli M, White I, Lendahl U (November 1994). "The human NOTCH1, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p13.1 in regions of neoplasia-associated translocation". Genomics. 24 (2): 253–258. doi:10.1006/geno.1994.1613. PMID7698746.
Tournier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H, etal. (March 1993). "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12". Nature Genetics. 3 (3): 256–259. doi:10.1038/ng0393-256. PMID8485581. S2CID13031278.
Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, etal. (October 1996). "Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia". Nature. 383 (6602): 707–710. Bibcode:1996Natur.383..707J. doi:10.1038/383707a0. PMID8878478. S2CID4351873.
Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C, etal. (November 1997). "Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients". Lancet. 350 (9090): 1511–1515. doi:10.1016/S0140-6736(97)08083-5. PMID9388399. S2CID38044421.
Joutel A, Chabriat H, Vahedi K, Domenga V, Vayssière C, Ruchoux MM, etal. (May 2000). "Splice site mutation causing a seven amino acid Notch3 in-frame deletion in CADASIL". Neurology. 54 (9): 1874–1875. doi:10.1212/wnl.54.9.1874. PMID10802807. S2CID19374887.
Shimizu K, Chiba S, Saito T, Kumano K, Hirai H (September 2000). "Physical interaction of Delta1, Jagged1, and Jagged2 with Notch1 and Notch3 receptors". Biochemical and Biophysical Research Communications. 276 (1): 385–389. Bibcode:2000BBRC..276..385S. doi:10.1006/bbrc.2000.3469. PMID11006133.
Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD (December 2000). "MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors". Nature Genetics. 26 (4): 484–489. doi:10.1038/82644. PMID11101851. S2CID23335042.
Dichgans M, Herzog J, Gasser T (November 2001). "NOTCH3 mutation involving three cysteine residues in a family with typical CADASIL". Neurology. 57 (9): 1714–1717. doi:10.1212/wnl.57.9.1714. PMID11706120. S2CID21180235.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.